Mills GB - Search Results

1

BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer.

Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. Rai R, et al. Among authors: mills gb. Cancer Cell. 2006 Aug;10(2):145-57. doi: 10.1016/j.ccr.2006.07.002. Epub 2006 Jul 27. Cancer Cell. 2006. PMID: 16872911 Free PMC article.

2

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr. Yu Y, et al. Among authors: mills gb. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9. doi: 10.1073/pnas.96.1.214. Proc Natl Acad Sci U S A. 1999. PMID: 9874798 Free PMC article.

3

In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. Hu L, et al. Among authors: mills gb. Clin Cancer Res. 2000 Mar;6(3):880-6. Clin Cancer Res. 2000. PMID: 10741711

4

An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.

Suzuki S, Moore DH 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. Suzuki S, et al. Cancer Res. 2000 Oct 1;60(19):5382-5. Cancer Res. 2000. PMID: 11034075

5

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. Mills GB, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41. doi: 10.1016/s0093-7754(01)90290-8. Semin Oncol. 2001. PMID: 11706404 Review.

6

Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.

Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Mills GB, et al. Cancer Treat Res. 2002;107:259-83. doi: 10.1007/978-1-4757-3587-1_12. Cancer Treat Res. 2002. PMID: 11775454 Review.

7

Specific keynote: molecular therapeutics in ovarian cancer.

Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.

8

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Mills GB, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):93-104. doi: 10.1053/j.seminoncol.2003.08.011. Semin Oncol. 2003. PMID: 14613030 Review.

9

Determinants of rapamycin sensitivity in breast cancer cells.

Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F. Noh WC, et al. Among authors: mills gb. Clin Cancer Res. 2004 Feb 1;10(3):1013-23. doi: 10.1158/1078-0432.ccr-03-0043. Clin Cancer Res. 2004. PMID: 14871980

10

A genetically defined model for human ovarian cancer.

Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC Jr. Liu J, et al. Among authors: mills gb. Cancer Res. 2004 Mar 1;64(5):1655-63. doi: 10.1158/0008-5472.can-03-3380. Cancer Res. 2004. PMID: 14996724

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,137 results

Search Page